This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rochlitz, C. F. Articles by Benz, C. C. Search for Related Content PubMed PubMed Citation Articles by Rochlitz, C. F. Articles by Benz, C. C.

Incidence of Activating ras Oncogene Mutations Associated with Primary and Metastatic Human Breast Cancer¹

Cancer Research Institute, University of California at San Francisco, San Francisco, California 94143 [C. F. R., G. K. S., J. M. D., E. L., C. C. B.], and Peralta Cancer Research Institute, Oakland, California 94609 [C. D., H. S. S.]

To test the hypothesis that ras activation is involved in the final stages of breast cancer progression, we analyzed tumor DNA derived from 60 different patients and extracted from 40 invasive primary breast tumors, seven lymph node and skin metastases, nine metastatic effusions, and five established breast cancer cell lines. The polymerase chain reaction technique was used to amplify DNA fragments containing Kirsten-(Ki-), Harvey-(Ha-), and N-ras codons 12, 13, and 61 which were then probed on slot-blots with labeled synthetic oligomers to detect nonconservative single base mutations. Activating mutations were found in one of 40 primary tumors (Ki-ras codon 13), zero of seven lymph node and skin metastases, one of nine metastatic effusions (Ki-ras codon 12), and two of five cell lines (Ki-ras codons 12 and 13). These results indicate that activating ras mutations are rarely involved in either the initiation or metastatic progression of human breast cancer.

¹ This work was supported in part by Grants CA-44768 and CA-36773 from the National Cancer Institute and CH-235 from the American Cancer Society.

² Recipient of support from a grant from the German Volkswagon Stiftung, Hanover, West Germany. Present address: Free University of Berlin, Berlin, West Germany.

³ Present address: Lineberger Cancer Research Center, Chapel Hill, NC 27599.

⁴ To whom requests for reprints should be addressed.

Received 7/18/88. Revised 10/14/88. Accepted 10/20/88.

This article has been cited by other articles:

				J. A. Sparano, S. Moulder, A. Kazi, D. Coppola, A. Negassa, L. Vahdat, T. Li, C. Pellegrino, S. Fineberg, P. Munster, et al. Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer Clin. Cancer Res., April 15, 2009; 15(8): 2942 - 2948. [Abstract] [Full Text] [PDF]

				O. K. Mirzoeva, D. Das, L. M. Heiser, S. Bhattacharya, D. Siwak, R. Gendelman, N. Bayani, N. J. Wang, R. M. Neve, Y. Guan, et al. Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition Cancer Res., January 15, 2009; 69(2): 565 - 572. [Abstract] [Full Text] [PDF]

				J. W. Jang, R. B. Boxer, and L. A. Chodosh Isoform-Specific Ras Activation and Oncogene Dependence during MYC- and Wnt-Induced Mammary Tumorigenesis Mol. Cell. Biol., November 1, 2006; 26(21): 8109 - 8121. [Abstract] [Full Text] [PDF]

				J. S. Tront, B. Hoffman, and D. A. Liebermann Gadd45a Suppresses Ras-Driven Mammary Tumorigenesis by Activation of c-Jun NH2-Terminal Kinase and p38 Stress Signaling Resulting in Apoptosis and Senescence. Cancer Res., September 1, 2006; 66(17): 8448 - 8454. [Abstract] [Full Text] [PDF]

				M. J. Campbell, L. J. Esserman, Y. Zhou, M. Shoemaker, M. Lobo, E. Borman, F. Baehner, A. S. Kumar, K. Adduci, C. Marx, et al. Breast Cancer Growth Prevention by Statins. Cancer Res., September 1, 2006; 66(17): 8707 - 8714. [Abstract] [Full Text] [PDF]

				J. A. Sparano, S. Moulder, A. Kazi, L. Vahdat, T. Li, C. Pellegrino, P. Munster, M. Malafa, D. Lee, S. Hoschander, et al. Targeted Inhibition of Farnesyltransferase in Locally Advanced Breast Cancer: A Phase I and II Trial of Tipifarnib Plus Dose-Dense Doxorubicin and Cyclophosphamide J. Clin. Oncol., July 1, 2006; 24(19): 3013 - 3018. [Abstract] [Full Text] [PDF]

				R. De Maria, M. Olivero, S. Iussich, M. Nakaichi, T. Murata, B. Biolatti, and M. F. Di Renzo Spontaneous Feline Mammary Carcinoma Is a Model of HER2 Overexpressing Poor Prognosis Human Breast Cancer Cancer Res., February 1, 2005; 65(3): 907 - 912. [Abstract] [Full Text] [PDF]

				S. E. Shackney, C. A. Smith, A. Pollice, K. Brown, R. Day, T. Julian, and J. F. Silverman Intracellular Patterns of Her-2/neu, ras, and Ploidy Abnormalities in Primary Human Breast Cancers Predict Postoperative Clinical Disease-Free Survival Clin. Cancer Res., May 1, 2004; 10(9): 3042 - 3052. [Abstract] [Full Text] [PDF]

				J. E. Green, K. V. Desai, Yumei Ye, C. Kavanaugh, A. Calvo, and J.-I. Huh Application of Gene Expression Profiling for Validating Models of Human Breast Cancer Toxicol Pathol, January 1, 2004; 32(1_suppl): 84 - 89. [Abstract] [PDF]

				Z. Ma, D. J. Webb, M. Jo, and S. L. Gonias Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells J. Cell Sci., March 11, 2002; 114(18): 3387 - 3396. [Abstract] [Full Text] [PDF]

				K. Wu, H.-T. Kim, J. L. Rodriquez, D. Munoz-Medellin, S. K. Mohsin, S. G. Hilsenbeck, W. W. Lamph, M. M. Gottardis, M. A. Shirley, J. G. Kuhn, et al. 9-cis-Retinoic Acid Suppresses Mammary Tumorigenesis in C3(1)-Simian Virus 40 T Antigen-transgenic Mice Clin. Cancer Res., September 1, 2000; 6(9): 3696 - 3704. [Abstract] [Full Text]

				C. A. Smith, A. A. Pollice, L.-P. Gu, K. A. Brown, S. G. Singh, L. E. Janocko, R. Johnson, T. Julian, D. Hyams, N. Wolmark, et al. Correlations Among p53, Her-2/neu, and ras Overexpression and Aneuploidy by Multiparameter Flow Cytometry in Human Breast Cancer: Evidence for a Common Phenotypic Evolutionary Pattern in Infiltrating Ductal Carcinomas Clin. Cancer Res., January 1, 2000; 6(1): 112 - 126. [Abstract] [Full Text]

				D Alford, D Baeckstrom, M Geyp, P Pitha, and J Taylor-Papadimitriou Integrin-matrix interactions affect the form of the structures developing from human mammary epithelial cells in collagen or fibrin gels J. Cell Sci., January 2, 1998; 111(4): 521 - 532. [Abstract] [PDF]

				E. H. Radany, K. Hong, S. Kesharvarzi, E. S. Lander, and J. M. Bishop Mouse mammary tumor virus/v-Ha-ras transgene-induced mammary tumors exhibit strain-specific allelic loss on mouse chromosome 4 PNAS, August 5, 1997; 94(16): 8664 - 8669. [Abstract] [Full Text] [PDF]

				S. Kato, H. Endoh, Y. Masuhiro, T. Kitamoto, S. Uchiyama, H. Sasaki, S. Masushige, Y. Gotoh, E. Nishida, H. Kawashima, et al. Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase Science, December 1, 1995; 270(5241): 1491 - 1494. [Abstract] [PDF]